8-K: Catheter Precision Announces Departure of Chief Commercial Officer Marie-Claude Jacques

Catheter Precision, Inc. announced the discontinuation of employment for its Chief Commercial Officer, Marie-Claude Jacques, with CEO David Jenkins temporarily assuming the role.

Summary

• Catheter Precision, Inc. (the "Company") discontinued the employment of Marie-Claude Jacques, who served as the Company's Chief Commercial Officer.
• The discontinuation of employment was effective on June 2, 2025.
• David Jenkins, the Company's Executive Chairman of the Board and Chief Executive Officer, will temporarily fill the role of Chief Commercial Officer.
• Mr. Jenkins will serve in this interim capacity until a permanent replacement is engaged.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the departure of a key C-suite executive, which can introduce uncertainty. However, the immediate interim appointment of the CEO mitigates the leadership vacuum, preventing a more significant negative score.

Negatives

• The departure of a Chief Commercial Officer can introduce uncertainty regarding the company's commercial strategy and execution.

Risks

• Potential disruption to the company's commercial operations and sales initiatives due to the change in leadership.
• Uncertainty regarding the timeline and success of finding a suitable permanent replacement for the Chief Commercial Officer role.

Future Outlook

The document does not provide any forward-looking statements or financial guidance beyond the interim appointment of the Chief Commercial Officer.

Industry Context

This announcement pertains to an internal executive change within Catheter Precision, Inc., a company operating in the medical device sector, specifically focused on catheter precision technologies. The document does not provide broader industry context or trends.

Management Changes

Stakeholder Impact

• Shareholders may experience uncertainty regarding the continuity and effectiveness of the company's commercial strategy.
• Employees within the commercial department may face changes in leadership and reporting structures.
• Customers and suppliers might experience temporary adjustments in their primary points of contact or commercial interactions.

Next Steps

• The company will engage in the process of finding and appointing a permanent replacement for the Chief Commercial Officer role.

Key Dates

Keywords

Catheter Precision, VTAK, SEC filing, 8-K, Chief Commercial Officer, CCO, executive change, management change, corporate governance, medical devices